Schrödinger Announces Collaboration with AstraZeneca to Deploy Advanced Computing Technology for Drug Discovery
Schrödinger today announced a collaboration with AstraZeneca to deploy Schrödinger’s advanced computing platform to help accelerate drug discovery efforts.
Schrödinger’s computational platform combines physics-based modeling and machine learning to enable chemists to predict the potency of a molecule binding to a target protein. This increases the likelihood that, when synthesized, compounds will have the correct properties required for further development and reduces the number of compounds that need to be synthesized.
Schrödinger’s platform will be used by AstraZeneca’s medicinal and computational chemists to help improve the design of compounds to identify potential new therapeutic candidates.
To ensure a comprehensive knowledge transfer, Schrödinger’s team will work closely and share best practices with AstraZeneca to help integrate the platform into their drug discovery workflow.
Garry Pairaudeau, Global Chemistry Lead, R&D, AstraZeneca, commented: “Our strategic goal is to transform drug design using innovative digital technologies. In this collaboration with Schrödinger, we look forward to realizing the potential of predictive physics-based modeling and machine learning to help us deliver higher quality compounds more effectively.”
“We are excited to launch this collaboration. AstraZeneca is a leader in embracing the potential of technology to reshape drug discovery, and we look forward to supporting them to deliver their vision for the future of drug design,” said Schrödinger CEO Ramy Farid, Ph.D.
Schrödinger’s industry-leading computational platform to accelerate drug discovery and materials design is deployed by leading pharmaceutical, biotechnology, chemical, and electronics companies worldwide. In addition to this substantial and growing global business, Schrödinger has built a robust pipeline of therapeutic assets, held both internally and in partnerships, and has co-founded leading biotech companies, including Nimbus Therapeutics and Morphic Therapeutic. Schrödinger’s significant and ongoing investment in basic research continues to drive advances in its computational platform. Founded in 1990, Schrödinger has nearly 400 employees in its New York City headquarters and around the world. Visit schrodinger.com for more information.
Ten Bridge Communications
Stern IR, Inc.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GSMA Condemns Attacks Against Mobile Phone Masts5.4.2020 16:11:00 EEST | Press release
Police and counter-terrorism authorities are investigating acts of arson against mobile phone masts in the UK. The GSMA condemns these acts of violence designed to weaken our communications networks in a time of crisis. Our vision at the GSMA is to unlock the power of connectivity so that people, industry and society thrive. We must unite in the global fight against COVID-19 and combat the fake news and violent actions linking 5G communications technology to the spread of the virus. This disinformation campaign is inciting fear, aggression, and vandalism against the critical infrastructure and essential maintenance workers who are keeping our public services connected, as well as our economy running. England’s National Medical Director Stephen Powis has been widely reported in the media as saying, “The 5G story is complete and utter rubbish, it’s nonsense, it’s the worst kind of fake news.” The GSMA calls on internet giants, content providers and social media platforms to accelerate th
Piper Sandler Completes Acquisition of Preeminent Chemicals Investment Bank, The Valence Group4.4.2020 00:13:00 EEST | Press release
Piper Sandler Companies (NYSE: PIPR), a leading investment bank and institutional securities firm, today announced it has completed its acquisition of The Valence Group, a premier international investment bank specializing in the chemicals, materials and related sectors. The Valence Group will operate as Piper Sandler’s new chemicals & materials group, adding yet another industry-leading advisory practice to the Piper Sandler platform. In addition, Peter Hall, one of the founders of The Valence Group, will now lead Piper Sandler’s expansion of investment banking in Europe. Piper Sandler was advised by its wholly owned subsidiary, Piper Sandler & Co., and was represented by Sullivan & Cromwell LLP. Houlihan Lokey served as financial advisor and Dentons as legal advisor to The Valence Group in connection with the transaction. About Piper Sandler Piper Sandler is a leading investment bank and institutional securities firm driven to help clients Realize the Power of Partnership®. Through a
BitHull Overtakes ASIC Market with New FPGA Miners3.4.2020 20:38:00 EEST | Press release
BitHull S.A. ( www.BitHull.com ) is pleased to announce the launch of its two new crypto miners BH Miner and BH Miners Box. These miners have been built around Field Programmable Gate Array or FPGA mining technology, the latest breakthrough in crypto mining. FPGA mining makes use of the new generation of FPGA chips capable of delivering high hash rate power at low power consumption. Owing to its outstanding features, FPGA mining is expected to overtake ASIC mining very soon. BH Miner and BH Miners Box are multi-algorithm miners capable of mining bitcoin, litecoin, ethereum, and monero. BH Miners Box is a box combining 6 BH Miner units connected to each other. Mentioned below are the key features of the two miners. BH Miner Hash Rates: Bitcoin: 360 TH/s, Litecoin: 60 GH/s, Ethereum: 15 GH/s, and Monero: 3 MH/s BH Miners Box: Bitcoin: 2160 TH/s, Litecoin: 360 GH/s, Ethereum: 90 GH/s, and Monero: 18 MH/s Power consumption: 550W and 550W x6 for BH Miner and BH Miners Box respectively The o
Celltrion’s COVID-19 Antiviral Treatment Enters the Next Phase of Development3.4.2020 11:00:00 EEST | Press release
Celltrion Group today announced its successful transition to the second phase of development for an antiviral treatment to fight the novel coronavirus (COVID-19) pandemic, following the completion of the first phase of securing 300 different types of antibodies that bind to the antigen last month. The library of antibodies was created using the blood of recovered patients in Korea. In cooperation with the Korea Centers for Disease Control and Prevention (KCDC), Celltrion will be screening the antibodies to find the ones most effective in neutralising SARS-CoV-2, the virus responsible for COVID-19. Celltrion anticipates the candidate screening for the therapeutic monoclonal antibody (mAb) will be complete by mid-April, sooner than originally expected. Ki-Sung Kwon, Head of R&D Unit at Celltrion said, “Once we have selected the one that most effectively neutralizes the COVID-19 virus among hundreds of the screened antibodies, we will roll out mass production of the therapeutic antibody t
Oracle Water System of MAK Leads Prevention of COVID-19 in Korea3.4.2020 08:18:00 EEST | Press release
The ozone water produced by Oracle Water System was proved to be effective in preventing epidemics as it was used in Korea which is recognized as an exemplary country in addressing Coronavirus Disease-19 (COVID-19) drawing attention from the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200402005897/en/ The ozone water ‘Oracle Water’ produced by Oracle Water System was proved to be effective in preventing epidemics as it was used in Korea which is recognized as an exemplary country in addressing COVID-19 drawing attention from the world. ‘Oracle Water’ was begun to be used as sterilizing water in Daegu, Korea and demonstrated the remarkable effect of preventing COVID-19. The number of confirmed COVID-19 cases in the city decreased from 390 on March 7 when the sterilizing water was begun to be used to 297 cases on March 8, 190 cases on March 9 and to 32 cases on March 17, showing a reduction by 91.7%. Using plasma, Or
Strategic Investment of NXP in Kalray3.4.2020 00:52:00 EEST | Press release
Kalray (Euronext Growth Paris : ALKAL – the “Company”), a pioneer in processors for new intelligent systems, today announces a strategic investment from NXP Semiconductors N.V. (NASDAQ: NXPI) for €8 million (approximately US$9 million), to enable the companies to develop together safe, reliable and scalable solutions for autonomous driving, combining NXP Automotive solutions and Kalray MPPA® (Massively Parallel Processor Array) Intelligent Processors. The investment will be carried out through the reserved issuance to NXP BV, a company of the NXP Group, of 503,461 ordinary shares without pre-emptive rights for the existing shareholders of the Company. Upon settlement-delivery of the new shares, the NXP Group will hold ca. 9.95% of Kalray’s share capital and voting rights. The settlement-delivery of the new shares is scheduled for April 7, 2020 and their admission to the Euronext Growth Paris multilateral trading system is scheduled for April 8, 2020. STRATEGIC NATURE OF THE TRANSACTION
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom